BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.
about
Shifting ecologies of malignant and nonmalignant cells following BRAF inhibition.Tissue-specific tumorigenesis: context matters.The experimental power of FR900359 to study Gq-regulated biological processes.Activation loop phosphorylation regulates B-Raf in vivo and transformation by B-Raf mutants.BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation.Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL.Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia.Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles.Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells.Vemurafenib-induced progression of breast cancer: a case report and review of the literature.Modulation of B-cell receptor and microenvironment signaling by a guanine exchange factor in B-cell malignanciesCooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment.Regulation of MAPK signaling and implications in chronic lymphocytic leukemia.Discrete cytosolic macromolecular BRAF complexes exhibit distinct activities and composition.Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo.Resolution of lung adenocarcinoma after discontinuation of ibrutinib.From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards.Development of chronic lymphocytic leukaemia during ipilimumab therapy in a patient with metastatic melanoma.
P2860
Q35140015-97CBEE6D-B3C3-458E-B3F1-507A1097F6D5Q36296335-0F6EDF27-2268-4D4E-A4A4-46468D923038Q36379426-3CBA5192-3D6C-46DE-A394-A48258956D2BQ36478826-9E8DF83B-C65C-4130-B9C7-342BBF05EA29Q36654999-34CA7C3A-A6F1-43E0-B48A-EE6F594DFD6AQ36897123-9C724F23-2C14-4619-812E-D187F2ED3912Q37212864-C751F04C-1464-40D2-B38B-4EB20B563455Q37295744-4DE4F480-2C6D-4049-BCDD-876758DBD14AQ37584298-06DA3F7C-6193-4D91-94D2-F1640ECA5E0BQ38564626-985F6308-6339-4ABB-B442-B14415030EE6Q38755788-6693A62B-4BB4-4B89-A1FE-D39ADB01E9D9Q40305624-ACF61132-EEE5-480E-B8DA-802F16B8C16FQ41370055-A07B3D2D-5CA9-4065-83E7-9DCBB64DDA3BQ47170848-2BC75CAB-7658-4F81-8AF5-2C78A7F1DDB4Q47840209-C9E28D54-54BA-4A9B-B170-4F85EC131BB9Q48348507-2399BBBF-44AD-48CE-850C-A29E00AECF04Q50042449-8DFCD430-8F0B-4060-B6F4-1D4FE0A11C12Q51630250-A89A20ED-DEE4-4B9C-98D4-CF4E59D0CEAAQ52354170-E38DE538-4159-4D1D-9F86-61576417B820Q52924613-CC607C52-A7EC-45FF-BEA8-1EF6182B6DB2
P2860
BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
BRAF inhibitor-associated ERK ...... chronic lymphocytic leukemia.
@ast
BRAF inhibitor-associated ERK ...... chronic lymphocytic leukemia.
@en
type
label
BRAF inhibitor-associated ERK ...... chronic lymphocytic leukemia.
@ast
BRAF inhibitor-associated ERK ...... chronic lymphocytic leukemia.
@en
prefLabel
BRAF inhibitor-associated ERK ...... chronic lymphocytic leukemia.
@ast
BRAF inhibitor-associated ERK ...... chronic lymphocytic leukemia.
@en
P2093
P2860
P50
P356
P1476
BRAF inhibitor-associated ERK ...... chronic lymphocytic leukemia.
@en
P2093
Dietmar Pfeifer
Frank Meiss
Hana Andrlova
Ingrid Bartsch
Justin Mastroianni
Justus Duyster
Katja Zirlik
Milena Pantic
Nimitha R Mathew
Niuscha Yaktapour
P2860
P304
P356
10.1172/JCI76539
P407
P577
2014-10-20T00:00:00Z